Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00421733 · ClinicalTrials.gov registry record · Phase 2
The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors
A Phase 2 study of Chronic Kidney Disease and Diabetic Nephropathy, sponsored by Abbott.
- Completed
- Registry status
- Phase 2
- Development phase
- 281
- Enrollment target
- 20
- Study locations
NCT00421733: Completed Phase 2 study of Chronic Kidney Disease and Diabetic Nephropathy, sponsored by Abbott.
NCT00421733 is a Phase 2 study of Chronic Kidney Disease and Diabetic Nephropathy that has completed, run by Abbott. The registered enrollment target is 281 participants, below the 3,204-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00421733, a Phase 2 study of Chronic Kidney Disease and Diabetic Nephropathy, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 281 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study objective was to evaluate the safety of paricalcitol capsules and the efficacy of paricalcitol capsules for albuminuria reduction in patients with Chronic Kidney Disease (CKD) who have Type 2 diabetic nephropathy and are receiving optimal angiotensin converting enzyme (ACE) inhibitor and/or angiotensin II receptor blocker (ARB) therapy.
Primary Outcome
UACR is defined as the ratio: milligram of albumin per gram of creatinine. Baseline UACR was determined as the mean of the 3 UACR measurements from FMV urine collections obtained within 1 week prior to the day of the first dose of study drug. The last on-treatment measurement was the mean of the 3 UACR measurements obtained from FMV urine collections obtained within 1 week of the final week of treatment. The UACR data were log transformed prior to analysis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Zemplar (paricalcitol ) capsules
- DRUG Zemplar (paricalcitol) capsules
Study Locations (20)
Florida
- Site Reference ID/Investigator# 853 - Hudson
- Site Reference ID/Investigator# 867 - Lauderdale Lakes
- Site Reference ID/Investigator# 857 - Pembroke Pines
- Site Reference ID/Investigator# 8901 - West Palm Beach
North Carolina
- Site Reference ID/Investigator# 866 - Charlotte
- Site Reference ID/Investigator# 8039 - Greenville
- Site Reference ID/Investigator# 8053 - Morehead City
California
- Site Reference ID/Investigator# 864 - Fountain Valley
- Site Reference ID/Investigator# 7291 - Yuba City
Illinois
- Site Reference ID/Investigator# 2531 - Chicago
- Site Reference ID/Investigator# 3371 - Evanston
Arizona
- Site Reference ID/Investigator# 862 - Phoenix
Georgia
- Site Reference ID/Investigator# 7113 - Roswell
Indiana
- Site Reference ID/Investigator# 869 - Indianapolis
Louisiana
- Site Reference ID/Investigator# 8054 - Baton Rouge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 281 participants |
| Start Date | 2006-12 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
What the finished NCT00421733 record still lists
NCT00421733 is an interventional study that assigns participants to a tested intervention. The registered 281 participants enrollment target is mid-sized for trials with a published cap, below the 3,204-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (91% lower).
The record links to 2 conditions, with Chronic Kidney Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00421733 names 20 study sites across 13 states, led by Florida, North Carolina, California.
Frequently Asked Questions
What is clinical trial NCT00421733 about?
NCT00421733 is a clinical study titled "The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors". The study objective was to evaluate the safety of paricalcitol capsules and the efficacy of paricalcitol capsules for albuminuria reduction in patients with Chronic Kidney Disease (CKD) who have Type 2 diabetic nephropathy and are receiving optimal angiotensin converting enzyme (ACE) inhibitor and/o...
What is the current status of trial NCT00421733?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 281 participants. The study started on 2006-12. Estimated completion is 2009-06.
What conditions does trial NCT00421733 study?
This clinical trial studies the following conditions: Chronic Kidney Disease, Diabetic Nephropathy.
What interventions are being tested in trial NCT00421733?
The interventions under investigation include: Placebo (DRUG), Zemplar (paricalcitol ) capsules (DRUG), Zemplar (paricalcitol) capsules (DRUG).
Who is sponsoring clinical trial NCT00421733?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00421733 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00421733's enrollment target sits among peer trials
281 31st of 101 higher than 71 of 101 other Chronic Kidney Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Kidney Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease: Sympatholysis in CKD
RECRUITING · Phase 2
-
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
RECRUITING · Phase 2
-
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
RECRUITING · Phase 2
-
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease
ACTIVE NOT RECRUITING · Phase 2
-
Metformin in Kidney Disease
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04521231 · 281 participants · Phase 1
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
- NCT06190730 · 281 participants · NA
REmote Symptom COllection to improVE postopeRative Care
- NCT02860364 · 282 participants · NA
Comparing Hypothermic Temperatures During Hemiarch Surgery
- NCT04867395 · 282 participants · NA
A Multi-Phase Study Examining Hospital to Home Transitions for Children With Medical Complexity
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia